We firmly believe that innovation begins with collision, and breakthroughs stem from persistence. We remain steadfast in our mission to deliver leading-edge quality and uncompromising standards. Every gram of peptide we produce represents the crystallization of our scientific wisdom. Since its founding in 2022, Utide has consistently pursued progress and sustained innovation. Currently, the company has achieved commercial-scale production of peptide , including semaglutide, tirzepatide, and retatrutide, and has obtained ISO9001, ISO14001 & ISO45001 system certifications.

At this stage, the company possesses an annual supply capacity of 1500 kilograms of peptide, establishing itself as a leading supplier of peptide products. At Utide, we believe technology empowers the future, and innovation runs through our veins. We will continue to leverage cutting-edge R&D processes, adhere to stringent quality standards, and serve our global clientele.